NDAORALSOLUTION
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
QBRELIS (lisinopril) by R-Pharm US is angiotensin-converting enzyme (ace) in human subjects and animals. First approved in 2016.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QBRELIS is an oral solution formulation of lisinopril, an ACE inhibitor approved in 2016 for hypertension and heart failure. It works by inhibiting angiotensin-converting enzyme, thereby suppressing the renin-angiotensin-aldosterone system and reducing vasopressor activity. The mechanism results in decreased blood pressure and improved cardiac function across diverse patient populations.
$0.001BPart D
Peak9.4 years to LOEQBRELIS is in peak commercial stage with modest Part D penetration ($1M spending, 883 claims in 2023), suggesting a niche oral solution product with limited team expansion opportunities.
Mechanism of Action
angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of…
Indications
Worked on QBRELIS at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.